MARYLAND HEIGHTS, Mo. & IRVINE, Calif.--(BUSINESS WIRE)--Sep. 14, 2015--
Masimo
(NASDAQ: MASI) today announced that Ranken Jordan Pediatric Bridge
Hospital has upgraded their monitors to the Radical-7 featuring Masimo
SET® pulse oximetry.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150914005482/en/
Ranken Jordan Pediatric Bridge Hospital (Photo: Business Wire)
“For children with complex medical conditions such as brain injuries,
congenital defects or complications due to premature birth, our hospital
specializes in bridging the gap between traditional hospital treatments
and going home,” said Laureen K. Tanner, RN, MSN, FACHE, President and
Chief Executive Officer of Ranken Jordan Pediatric Bridge Hospital.
“Breakthrough medical technology like this helps our team make the
impossible possible on a daily basis.”
The Radical-7 features Masimo SET® Measure-through-Motion and Low
Perfusion™ pulse oximetry, shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms.1,2
The benefits of Masimo SET® have been proven in more than 100
independent and objective studies and used on more than 100 million
patients in leading hospitals.3,4 Researchers have found that
Masimo SET®, in combination with changes in clinical practice, led to a
reduction in severe retinopathy of prematurity (ROP) in pre-term infants.5
In a study of newborns, researchers have found critical congenital heart
disease (CCHD) was detected 63% of the time by standard screening and
83% of the time when screening with Masimo SET® was added.6
The Radical-7 allows hospitals the ability to upgrade their monitor with
other breakthrough measurements that are only available with Masimo
rainbow® technology.
“The amazing team at Ranken Jordan Pediatric Bridge Hospital has been
taking care of children with complex needs for over 70 years. They are
the only pediatric sub acute facility in Missouri and one of the largest
in the Midwest,” stated Joe Kiani, Founder and CEO of Masimo.
“Performance in challenging situations is key and we are happy that
their clinical team now has access to our flagship monitor. It is our
privilege to help facilities like Ranken Jordan help kids and families
safely transition from the acute care hospital to home.”
About Ranken Jordan Pediatric Bridge Hospital
Ranken Jordan offers care through a 62,000 square-foot, 34-bed inpatient
program and several outpatient
programs, including outpatient
therapy, intensive day
treatment, a physiatry
clinic and a comprehensive orthopedic
rehabilitation clinic. The current hospital building houses
ultramodern equipment and is specifically designed to entice patients to
get out of their rooms and engage in daily life-centered activities.
Ranken Jordan's Community
Program provides free recreational and educational programs for all
kids and their families. For more information, contact
us or call 314-872-6400. www.rankenjordan.org
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies that significantly improve patient care -
helping solve "unsolvable" problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET®, which virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo SET®
outperforms other pulse oximetry technologies, even under the most
challenging clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced rainbow Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability
Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).
In the U.S., Masimo rainbow® SET pulse CO-Oximeter
instruments and sensors are indicated to provide noninvasive monitoring
of arterial oxygen saturation (SpO2) and pulse rate (PR),
carboxyhemoglobin saturation (SpCO®), methemoglobin
saturation (SpMet®), total hemoglobin concentration (g/dl
SpHb), and/or respiration rate (RRa®). The devices are not
intended to replace laboratory measurements of hemoglobin and have not
been cleared by FDA to detect bleeding or reduce the amount or frequency
of red blood cell (RBC) transfusions. Additional information about
Masimo and its products may be found at www.masimo.com.
@MasimoInnovates
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo.
1 Barker SJ. Anesth Analg. 2002 Oct;95(4):967-72
2
Shah N et al. J. Clin Anesth. 2012 Aug; 24(5):385-91.
3
All studies available at http://www.masimo.com/cpub/clinical-evidence.htm
4
Data on file
5 Castillo A et al. Acta Paediatr.
2011 Feb;100(2):188-92
6 de-Wahl Granelli AD et al. BMJ.
2009;338
View source version on businesswire.com: http://www.businesswire.com/news/home/20150914005482/en/
Source: Masimo
Ranken Jordan Pediatric Bridge Hospital
Tyler Mathews
Marketing/Communications
314-872-6503
Tyler.mathews@rankenjordan.org
or
Masimo
Irene
Paigah
858-859-7001
irenep@masimo.com